Key facts
- This page summarizes Jeffrey Allen Morris's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2024, 19:19.
Jeffrey Allen Morris - 12 Aug 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PVCT
- Reported as of
- 12 Aug 2024
- Net transaction value
- +$756,467
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2024, 19:19:02 UTC
- Prior SEC filing
- 14 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Allen Morris
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Allen Morris filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 14 Aug 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2023.
- Current net transaction value: +$756,467.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PVCT
transaction
Series D-1 Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $756,467
- Shares
- +264,314
- Change %
- +6.6%
- Price
- $2.86*
- Shares after
- 4,260,061
- Date
- 12 Aug 2024
- Ownership
- Direct
- Footnotes
- F3
PVCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,000,000
- Date
- 12 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
PVCT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,500,000
- Date
- 12 Aug 2024
- Ownership
- By IRA
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock.
Footnote F2
The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan.
Footnote F3
The reporting person has sole voting and dispositive power over 4,260,061 shares of Series D-1 Convertible Preferred Stock, convertible into 42,600,610 shares of Common Stock.